The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval ...

NovoCure shows mixed results in NSCLC, strong financially but cautious sell recommendation due to limited progress outside ...

Fintel reports that on October 16, 2024, HC Wainwright & Co. upgraded their outlook for NovoCure (NasdaqGS:NVCR) from Neutral ...

Optune Lua is designed for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have experienced disease progression after platinum-based chemotherapy. Asaf Danziger, CEO of Novocure ...

“Novocure is committed to extending ... cancer-related death worldwide1, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It is estimated that ...

“Novocure is committed to extending survival ... Lung cancer is the most common cause of cancer-related death worldwide1, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all ...